Zkusit zdarma
Invivyd, Inc.

Invivyd, Inc.

IVVD
Cena:
$ 1.10
-0.01 (-0.90%)
Valuace
70
Růst
53
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript

Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript

12:31 14-05-2026

Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript...

Invivyd Q1 Earnings Call Highlights

Invivyd Q1 Earnings Call Highlights

12:16 14-05-2026

Invivyd NASDAQ: IVVD said its first quarter of 2026 was marked by continued progress in its pivotal ...

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

9:16 14-05-2026

Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Es...

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights

7:01 14-05-2026

Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% grow...

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

7:01 11-05-2026

Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody a...

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

7:01 07-05-2026

NEW HAVEN, Conn., May 07, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical...

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7:01 05-05-2026

NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that...

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

7:01 20-04-2026

Elia to speak at the premier gathering of policy makers, industry leaders, and health experts betwee...

Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody Candidate Transcript

Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Monoclonal Antibody Candidate Transcript

19:42 09-04-2026

Invivyd, Inc. (IVVD) Discusses Progress in REVOLUTION Clinical Program and Advancement of Measles Mo...

Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program

Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program

10:07 09-04-2026

The company said its Phase 3 DECLARATION trial evaluating VYD2311 for COVID-19 prevention has reache...

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

7:01 09-04-2026

NEW HAVEN, Conn., April 09, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced pr...

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7:01 06-04-2026

NEW HAVEN, Conn., April 06, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced th...

Invivyd, Inc. (NASDAQ:IVVD) Receives $8.00 Consensus Target Price from Brokerages

Invivyd, Inc. (NASDAQ:IVVD) Receives $8.00 Consensus Target Price from Brokerages

1:33 03-04-2026

Invivyd, Inc. (NASDAQ: IVVD - Get Free Report) has received a consensus recommendation of "Hold" fro...

Invivyd Announces Presentation at the World Vaccine Congress Washington

Invivyd Announces Presentation at the World Vaccine Congress Washington

16:05 30-03-2026

NEW HAVEN, Conn., March 30, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced th...

Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching

Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching

11:22 20-03-2026

Invivyd, Inc. is advancing VYD2311, a next-gen monoclonal antibody for COVID-19 prevention, with piv...

Invivyd, Inc. (NASDAQ:IVVD) Receives $8.00 Consensus Target Price from Brokerages

Invivyd, Inc. (NASDAQ:IVVD) Receives $8.00 Consensus Target Price from Brokerages

1:30 09-03-2026

Invivyd, Inc. (NASDAQ: IVVD - Get Free Report) has received an average recommendation of "Hold" from...

Invivyd Q4 Earnings Call Highlights

Invivyd Q4 Earnings Call Highlights

4:49 07-03-2026

Invivyd (NASDAQ: IVVD) executives used the company's fourth-quarter 2025 earnings call to outline pr...

Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript

Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript

11:25 05-03-2026

Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript...

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

7:03 05-03-2026

NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced fi...

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

7:01 05-03-2026

NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced th...

close

INVIVYD ALIGNS WITH THE U.S. FDA ON LIBERTY, A PHASE 3 TRIAL TO EVALUATE THE SAFETY OF VYD2311 ANTIBODY VERSUS MRNA COVID VACCINE, AND TO CHARACTERIZE THE SAFETY AND IMMUNOLOGY OF ANTIBODY AND VACCINE CO-ADMINISTRATION

03-02-2026
NEW HAVEN, CONN., FEB. 03, 2026 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED IT ...
Více zde

INVIVYD AND SPEAR STUDY GROUP ANNOUNCE PLAN FOR PHASE 2 STUDY OF VYD2311 FOR TREATMENT OF LONG COVID AND COVID VACCINE-INJURED INDIVIDUALS TO COMMENCE MID-2026

20-01-2026
NEW HAVEN, CONN., JAN. 20, 2026 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) AND THE SPEAR STUDY...
Více zde

INVIVYD REPORTS PRELIMINARY FOURTH QUARTER 2025 REVENUE AND RECENT BUSINESS HIGHLIGHTS

08-01-2026
NEW HAVEN, CONN., JAN. 08, 2026 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED PRE...
Více zde

INVIVYD EARNS FAST TRACK DESIGNATION FOR VYD2311, A VACCINE-ALTERNATIVE ANTIBODY TO PREVENT COVID

23-12-2025
NEW HAVEN, CONN., DEC. 23, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED THA...
Více zde

INVIVYD ANNOUNCES INITIATION OF DECLARATION CLINICAL TRIAL, A PHASE 3 PLACEBO-CONTROLLED PIVOTAL STUDY OF VYD2311, A VACCINE-ALTERNATIVE ANTIBODY TO PREVENT COVID

23-12-2025
NEW HAVEN, CONN., DEC. 23, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED INI...
Více zde

INVIVYD TO PARTICIPATE AT THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE

25-11-2025
NEW HAVEN, CONN., NOV. 25, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED THA...
Více zde

INVIVYD ANNOUNCES SELECTION OF POTENTIAL BEST-IN-CLASS RSV ANTIBODY CANDIDATE VBY329; TARGETING 2H 2026 IND READINESS

24-11-2025
NEW HAVEN, CONN., NOV. 24, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED IT ...
Více zde

INVIVYD ANNOUNCES PRICING OF $125 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

17-11-2025
NEW HAVEN, CONN., NOV. 17, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (INVIVYD) (NASDAQ: IVVD) TODAY ANN...
Více zde

INVIVYD ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

17-11-2025
NEW HAVEN, CONN., NOV. 17, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (INVIVYD) (NASDAQ: IVVD) TODAY ANN...
Více zde

INVIVYD REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

06-11-2025
NEW HAVEN, CONN., NOV. 06, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED FIN...
Více zde

INVIVYD TO HOST THIRD QUARTER 2025 FINANCIAL RESULTS AND CORPORATE UPDATE CALL ON NOVEMBER 6, 2025

03-11-2025
NEW HAVEN, CONN., NOV. 03, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD), A BIOPHARMACEUTICA...
Více zde

INVIVYD TO HOST WEBCAST ON THE REVOLUTION CLINICAL PROGRAM FOR VYD2311, A VACCINE-ALTERNATIVE ANTIBODY TO PREVENT COVID

28-10-2025
NEW HAVEN, CONN., OCT. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: INVIVYD, INC. (NASDAQ: IVVD) IS HOSTING TH...
Více zde

INVIVYD ANNOUNCES U.S. IND CLEARANCE AND ALIGNMENT WITH U.S. FDA ON PIVOTAL CLINICAL PROGRAM FOR VYD2311, A VACCINE-ALTERNATIVE ANTIBODY TO PREVENT COVID

06-10-2025
NEW HAVEN, CONN., OCT. 06, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED THA...
Více zde

INVIVYD APPOINTS PAUL B. BOLNO, M.D.

24-09-2025
NEW HAVEN, CONN., SEPT. 24, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED TH...
Více zde

INVIVYD ANNOUNCES APPOINTMENT OF KRISTIE KUHL AS CHIEF COMMUNICATIONS OFFICER

17-09-2025
NEW HAVEN, CONN., SEPT. 17, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED TH...
Více zde

SPEAR STUDY GROUP TO PRESENT ITS RECOMMENDED LONG COVID ANTIBODY STUDY DESIGN FEATURING INVIVYD'S VYD2311 AT RECOVER-TLC WORKSHOP SEPTEMBER 9-10, 2025

04-09-2025
WALTHAM, MASS., SEPT. 04, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED THAT...
Více zde

INVIVYD TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

27-08-2025
WALTHAM, MASS., AUG. 27, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED THAT ...
Více zde

INVIVYD ANNOUNCES CLOSING OF $57.5 MILLION PUBLIC OFFERING AND FULL EXERCISE OF THE UNDERWRITER'S OPTION TO PURCHASE ADDITIONAL SHARES

22-08-2025
WALTHAM, MASS., AUG. 22, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (INVIVYD) (NASDAQ: IVVD) TODAY ANNOU...
Více zde

INVIVYD ANNOUNCES PRICING OF $50 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

20-08-2025
WALTHAM, MASS., AUG. 20, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (INVIVYD) (NASDAQ: IVVD) TODAY ANNOU...
Více zde

INVIVYD ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

20-08-2025
WALTHAM, MASS., AUG. 20, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (INVIVYD) (NASDAQ: IVVD) TODAY ANNOU...
Více zde

INVIVYD ANNOUNCES CONTINUED NEUTRALIZING ACTIVITY OF PEMGARDA® (PEMIVIBART) AND VYD2311 AGAINST CURRENTLY DOMINANT SARS-COV-2 VARIANT XFG (“STRATUS”)

18-08-2025
WALTHAM, MASS., AUG. 18, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED POSIT...
Více zde

INVIVYD REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

14-08-2025
WALTHAM, MASS., AUG. 14, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED FINAN...
Více zde

INVIVYD ALIGNS WITH U.S. FDA ON RAPID PATHWAY TO FULL APPROVAL (BLA) OF VACCINE ALTERNATIVE MONOCLONAL ANTIBODY VYD2311 TO PROTECT AMERICAN ADULTS AND ADOLESCENTS FROM COVID-19

14-08-2025
ALIGNMENT FOLLOWS TYPE C MEETING FOR VYD2311 AS PREVIOUSLY DISCLOSED BLA PATHWAY FOR VYD2311 TO BE S...
Více zde

SCIENTIST DR. AKIKO IWASAKI JOINS SPEAR STUDY GROUP TO INVESTIGATE MONOCLONAL ANTIBODIES FOR LONG COVID AND COVID-19 POST-VACCINATION SYNDROME

23-07-2025
WALTHAM, MASS., JULY 23, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD), TODAY ANNOUNCED THE ...
Více zde

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) GUIDELINES RECOMMEND MONOCLONAL ANTIBODIES FOR COVID-19 PREVENTION IN PEOPLE WITH CANCER; NEW DATA PUBLISHED IN JAMA ONCOLOGY UNDERSCORE SEVERE IMPACT OF COVID-19 ON THIS POPULATION

21-07-2025
NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) GUIDELINES RECOMMEND MONOCLONAL ANTIBODIES FOR COVI...
Více zde

INVIVYD AND LEADING RESEARCHERS FORM SPEAR (SPIKE PROTEIN ELIMINATION AND RECOVERY) STUDY GROUP TO ASSESS THE EFFECTS OF MONOCLONAL ANTIBODY THERAPY FOR LONG COVID AND COVID-19 POST-VACCINATION SYNDROME

02-07-2025
INVIVYD FORMS SPEAR (SPIKE PROTEIN ELIMINATION AND RECOVERY) STUDY GROUP WITH RESEARCHES TO ASSESS E...
Více zde

INVIVYD ANNOUNCES POSITIVE FULL PHASE 1/2 CLINICAL DATA FOR VYD2311, A NEXT GENERATION COVID-19 MONOCLONAL ANTIBODY FOR POTENTIAL USE AS A NON-VACCINE PREVENTATIVE AND FOR TREATMENT OF ACTIVE INFECTION

26-06-2025
WALTHAM, MASS., JUNE 26, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD), TODAY ANNOUNCED FULL...
Více zde

INVIVYD ANNOUNCES PUBLICATION OF LANDMARK CANOPY PHASE 3 PEMGARDA® (PEMIVIBART) CLINICAL TRIAL; RESULTS UNDERSCORE STRONG EFFICACY OF MONOCLONAL ANTIBODIES IN PREVENTING COVID-19 IN A MODERN U.S. POPULATION AGAINST RELEVANT, IMMUNE-EVASIVE SARS-COV-2 VIRU

27-05-2025
WALTHAM, MASS., MAY 27, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED THAT R...
Více zde

INVIVYD ANNOUNCES INCLUSION OF PEMGARDA® (PEMIVIBART) IN NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CLINICAL PRACTICE GUIDELINES IN ONCOLOGY FOR B-CELL LYMPHOMAS

23-05-2025
WALTHAM, MASS., MAY 23, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD), TODAY ANNOUNCED THAT ...
Více zde

INVIVYD COMMENDS FDA FOCUS ON CONTEMPORARY EVIDENCE IN EVALUATING MEDICAL INTERVENTIONS TO PREVENT COVID-19

21-05-2025
FDA ACKNOWLEDGES THAT THE BENEFIT OF REPEAT DOSES OF COVID-19 VACCINE BOOSTERS FOR AMERICANS IS UNCE...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-08 00:00:008-KStáhnout
2025-12-23 00:00:008-KStáhnout
2025-11-24 00:00:008-KStáhnout
2025-11-19 00:00:008-KStáhnout
2025-11-06 00:00:008-KStáhnout
2025-11-06 00:00:0010-QStáhnout
2025-10-30 00:00:008-KStáhnout
2025-10-06 01:00:008-KStáhnout
2025-10-06 00:00:008-KStáhnout
2025-09-24 01:00:008-KStáhnout
2025-09-24 00:00:008-KStáhnout
2025-08-22 01:00:008-KStáhnout
2025-08-22 00:00:008-KStáhnout
2025-08-14 01:00:008-KStáhnout
2025-08-14 01:00:0010-QStáhnout
2025-08-14 00:00:008-KStáhnout
2025-08-14 00:00:0010-QStáhnout
2025-07-02 01:00:008-KStáhnout
2025-07-02 00:00:008-KStáhnout
2025-06-26 01:00:008-KStáhnout
2025-06-26 00:00:008-KStáhnout
2025-05-20 01:00:008-KStáhnout
2025-05-20 00:00:008-KStáhnout
2025-05-15 01:00:008-KStáhnout
2025-05-15 01:00:0010-QStáhnout
2025-05-15 00:00:008-KStáhnout
2025-05-15 00:00:0010-QStáhnout
2025-05-12 01:00:008-KStáhnout
2025-05-12 00:00:008-KStáhnout
2025-04-25 01:00:008-KStáhnout
2025-04-25 00:00:008-KStáhnout
2025-04-21 01:00:008-KStáhnout
2025-04-21 00:00:008-KStáhnout
2025-03-26 00:00:008-KStáhnout
2025-03-25 23:00:008-KStáhnout
2025-03-20 00:00:008-KStáhnout
2025-03-20 00:00:0010-KStáhnout
2025-03-19 23:00:008-KStáhnout
2025-03-19 23:00:0010-KStáhnout
2025-03-05 00:00:008-KStáhnout
2025-03-04 23:00:008-KStáhnout
2025-02-24 00:00:008-KStáhnout
2025-02-23 23:00:008-KStáhnout
2025-02-03 00:00:008-KStáhnout
2025-02-02 23:00:008-KStáhnout
2025-01-27 00:00:008-KStáhnout
2025-01-26 23:00:008-KStáhnout
2025-01-10 00:00:008-KStáhnout
2025-01-09 23:00:008-KStáhnout
2024-12-27 00:00:008-KStáhnout
2024-12-26 23:00:008-KStáhnout
2024-12-02 00:00:008-KStáhnout
2024-12-01 23:00:008-KStáhnout
2024-11-14 00:00:008-KStáhnout
2024-11-14 00:00:0010-QStáhnout
2024-11-13 23:00:008-KStáhnout
2024-11-13 23:00:0010-QStáhnout
2024-10-29 00:00:008-KStáhnout
2024-10-28 23:00:008-KStáhnout
2024-09-23 01:00:008-KStáhnout
2024-09-23 00:00:008-KStáhnout
2024-09-06 01:00:008-KStáhnout
2024-09-06 00:00:008-KStáhnout
2024-09-04 01:00:008-KStáhnout
2024-09-04 00:00:008-KStáhnout
2024-09-03 01:00:008-KStáhnout
2024-09-03 00:00:008-KStáhnout
2024-08-27 01:00:008-KStáhnout
2024-08-27 00:00:008-KStáhnout
2024-08-14 01:00:008-KStáhnout
2024-08-14 01:00:0010-QStáhnout
2024-08-14 00:00:008-KStáhnout
2024-08-14 00:00:0010-QStáhnout
2024-06-14 01:00:008-KStáhnout
2024-06-14 00:00:008-KStáhnout
2024-05-31 01:00:008-KStáhnout
2024-05-31 00:00:008-KStáhnout
2024-05-22 01:00:008-KStáhnout
2024-05-22 00:00:008-KStáhnout
2024-05-09 01:00:008-KStáhnout
2024-05-09 01:00:0010-QStáhnout
2024-05-09 00:00:008-KStáhnout
2024-05-09 00:00:0010-QStáhnout
2024-05-07 01:00:008-KStáhnout
2024-05-07 00:00:008-KStáhnout
2024-04-12 01:00:008-KStáhnout
2024-04-12 00:00:008-KStáhnout
2024-04-04 01:00:008-KStáhnout
2024-04-04 00:00:008-KStáhnout
2024-03-28 00:00:008-KStáhnout
2024-03-28 00:00:0010-KStáhnout
2024-03-27 23:00:008-KStáhnout
2024-03-27 23:00:0010-KStáhnout
2024-03-25 00:00:008-KStáhnout
2024-03-24 23:00:008-KStáhnout
2024-02-09 00:00:008-KStáhnout
2024-02-08 23:00:008-KStáhnout
2024-01-08 00:00:008-KStáhnout
2024-01-07 23:00:008-KStáhnout
2024-01-03 00:00:008-KStáhnout
2024-01-02 23:00:008-KStáhnout
2023-12-22 00:00:008-KStáhnout
2023-12-21 23:00:008-KStáhnout
2023-12-18 00:00:008-KStáhnout
2023-12-17 23:00:008-KStáhnout
2023-11-09 00:00:008-KStáhnout
2023-11-09 00:00:0010-QStáhnout
2023-11-08 23:00:008-KStáhnout
2023-11-08 23:00:0010-QStáhnout
2023-09-11 01:00:008-KStáhnout
2023-09-11 00:00:008-KStáhnout
2023-09-05 01:00:008-KStáhnout
2023-09-05 00:00:008-KStáhnout
2023-08-10 01:00:008-KStáhnout
2023-08-10 01:00:0010-QStáhnout
2023-08-10 00:00:008-KStáhnout
2023-08-10 00:00:0010-QStáhnout
2023-07-27 01:00:008-KStáhnout
2023-07-27 00:00:008-KStáhnout
2023-06-29 01:00:008-KStáhnout
2023-06-29 00:00:008-KStáhnout
2023-05-25 01:00:008-KStáhnout
2023-05-25 00:00:008-KStáhnout
2023-05-11 01:00:008-KStáhnout
2023-05-11 01:00:0010-QStáhnout
2023-05-11 00:00:008-KStáhnout
2023-05-11 00:00:0010-QStáhnout
2023-05-02 01:00:008-KStáhnout
2023-05-02 00:00:008-KStáhnout
2023-03-23 00:00:008-KStáhnout
2023-03-23 00:00:0010-KStáhnout
2023-03-22 23:00:008-KStáhnout
2023-03-22 23:00:0010-KStáhnout
2023-03-06 00:00:008-KStáhnout
2023-03-05 23:00:008-KStáhnout
2023-01-09 00:00:008-KStáhnout
2023-01-08 23:00:008-KStáhnout
2022-12-06 00:00:008-KStáhnout
2022-12-05 23:00:008-KStáhnout
2022-11-17 00:00:008-KStáhnout
2022-11-16 23:00:008-KStáhnout
2022-11-10 00:00:008-KStáhnout
2022-11-10 00:00:0010-QStáhnout
2022-11-09 23:00:008-KStáhnout
2022-11-09 23:00:0010-QStáhnout
2022-10-24 01:00:008-KStáhnout
2022-10-24 00:00:008-KStáhnout
2022-10-13 01:00:008-KStáhnout
2022-10-13 00:00:008-KStáhnout
2022-09-13 01:00:008-KStáhnout
2022-09-12 01:00:008-KStáhnout
2022-09-12 00:00:008-KStáhnout
2022-08-15 01:00:008-KStáhnout
2022-08-15 01:00:0010-QStáhnout
2022-07-05 01:00:008-KStáhnout
2022-06-30 01:00:008-KStáhnout
2022-06-22 01:00:008-KStáhnout
2022-06-21 01:00:008-KStáhnout
2022-05-19 01:00:008-KStáhnout
2022-05-13 01:00:008-KStáhnout
2022-05-13 01:00:0010-QStáhnout
2022-03-31 01:00:0010-KStáhnout
2022-03-30 01:00:008-KStáhnout
2022-03-21 00:00:008-KStáhnout
2022-03-01 00:00:008-KStáhnout
2022-02-23 00:00:008-KStáhnout
2022-02-22 00:00:008-KStáhnout
2022-02-18 00:00:008-KStáhnout
2022-01-13 00:00:008-KStáhnout
2021-12-14 00:00:008-KStáhnout
2021-11-29 00:00:008-KStáhnout
2021-11-22 00:00:008-KStáhnout
2021-11-16 00:00:008-KStáhnout
2021-11-15 00:00:008-KStáhnout
2021-11-15 00:00:0010-QStáhnout
2021-10-19 01:00:008-KStáhnout
2021-09-29 01:00:008-KStáhnout
2021-09-20 01:00:008-KStáhnout
2021-09-20 01:00:0010-QStáhnout
2021-09-10 01:00:008-KStáhnout
2021-08-10 01:00:008-KStáhnout
preloader